read the whole article but a bit underwhelming in my view. a missed opportunity to promote the company a bit more
the article mispresented that neuren is looking for financing option to commercialize PMS. The company is in fact fully funded to take it all the way to FDA approval. There's no mention of the strength of the cash position
no mention of the consensus valuation (ie north of $25)
no mention of the other new indications in the works
no mention of how the PMS end point agreement would benefit the upcoming Pitt Hopkins phase 3 discussion
no mention of how Neuren could potentially be the first to provide treatment for PMS and Pitt Hopkins
NEU Price at posting:
$11.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)